Osimertinib related cardiotoxicity in patients with non-small cell lung cancer

被引：0
|
作者：
Mensah, Samuel Akaakole [1 ]
Alruwaili, Waleed [1 ]
Ahmad, Syed [1 ]
Patel, Brijesh [1 ]
Almubarak, Mohammed [1 ]
机构：
[1] West Virginia Univ, Morgantown, WV 26506 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e20011
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Patterns of Failure in Stage IV Non-Small Cell Lung Cancer Patients Treated with Osimertinib
    Peoples, C.
    Wang, C.
    Yu, H.
    Yang, T. J.
    Rimner, A.
    Wu, A. J.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2019, 105 (01): : E527 - E527
  • [22] Osimertinib for the treatment of patients with EGFR mutation-positive non-small cell lung cancer
    Alsharedi, M.
    Bukamur, H.
    Elhamdani, A.
    DRUGS OF TODAY, 2018, 54 (06) : 369 - 379
  • [23] Population pharmacokinetics and exposure-response of osimertinib in patients with non-small cell lung cancer
    Brown, Kathryn
    Comisar, Craig
    Witjes, Han
    Maringwa, John
    de Greef, Rik
    Vishwanathan, Karthick
    Cantarini, Mireille
    Cox, Eugene
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2017, 83 (06) : 1216 - 1226
  • [24] Exosomal microRNAs as potential biomarkers for osimertinib resistance of non-small cell lung cancer patients
    Janpipatkul, Keatdamrong
    Trachu, Narumol
    Watcharenwong, Piyakarn
    Panvongsa, Wittaya
    Worakitchanon, Wittawin
    Metheetrairut, Chanatip
    Oranratnachai, Songporn
    Reungwetwattana, Thanyanan
    Chairoungdua, Arthit
    CANCER BIOMARKERS, 2021, 31 (03) : 281 - 294
  • [25] Osimertinib for treating Patients with EGFR Mutation-Positive non-small cell Lung Cancer
    Meinrenken, Susanne
    PNEUMOLOGIE, 2018, 72 (04): : 246 - 246
  • [26] Integrating Osimertinib in Clinical Practice for Non-Small Cell Lung Cancer Treatment
    Senthil Rajappa
    M. Vamshi Krishna
    Prasad Narayanan
    Advances in Therapy, 2019, 36 : 1279 - 1290
  • [27] Integrating Osimertinib in Clinical Practice for Non-Small Cell Lung Cancer Treatment
    Rajappa, Senthil
    Krishna, M. Vamshi
    Narayanan, Prasad
    ADVANCES IN THERAPY, 2019, 36 (06) : 1279 - 1290
  • [28] An overview of osimertinib as a treatment of non-small cell lung cancer (NSCLC): an update
    Cerbone, Luigi
    Benitez, Jose Carlos
    Planchard, David
    Genova, Carlo
    EXPERT OPINION ON PHARMACOTHERAPY, 2021, 22 (07) : 809 - 819
  • [29] Pharmacokinetic drug evaluation of osimertinib for the treatment of non-small cell lung cancer
    Rossi, Antonio
    Muscarella, Lucia Anna
    Di Micco, Concetta
    Carbonelli, Cristiano
    D'alessandro, Vito
    Notarangelo, Stefano
    Palomba, Giuseppe
    Sanpaolo, Gerardo
    Taurchini, Marco
    Graziano, Paolo
    Maiello, Evaristo
    EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2017, 13 (12) : 1281 - 1288
  • [30] Osimertinib resistance in non-small cell lung cancer: Mechanisms and therapeutic strategies
    Tang, Zheng-Hai
    Lu, Jin-Jian
    CANCER LETTERS, 2018, 420 : 242 - 246
12345